Theranexus (XPAR:ALTHX) Change In Inventory : €0.00 Mil (TTM As of Jun. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Theranexus Change In Inventory?

Theranexus's change in inventory for the quarter that ended in Jun. 2024 was €0.00 Mil. It means Theranexus's inventory stayed the same from Dec. 2023 to Jun. 2024 .

Theranexus's change in inventory for the fiscal year that ended in Dec. 2023 was €0.00 Mil. It means Theranexus's inventory stayed the same from Dec. 2022 to Dec. 2023 .

Theranexus's Total Inventories for the quarter that ended in Jun. 2024 was €0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Theranexus's Days Inventory for the quarter that ended in Jun. 2024 was 0.00.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Theranexus Change In Inventory Historical Data

The historical data trend for Theranexus's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theranexus Change In Inventory Chart

Theranexus Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Inventory

Get a 7-Day Free Trial

Theranexus Semi-Annual Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Change In Inventory	Get a 7-Day Free Trial													-	-	-	-	-

Theranexus Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

Theranexus (XPAR:ALTHX) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Theranexus's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0	/	1.293	*	365 / 2
	=	0.00

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Theranexus's Inventory Turnover for the quarter that ended in Jun. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	1.293	/	0
	=	N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Theranexus's Inventory to Revenue for the quarter that ended in Jun. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	0
	=	N/A

Theranexus Change In Inventory Related Terms

Thank you for viewing the detailed overview of Theranexus's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Theranexus Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theranexus SA (XPAR:ALTHX) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

3VG:Germany

Address

60 avenue Rockefeller, Pepiniere Laennec, Lyon, FRA, 69008

Website

https://www.theranexus.com

Theranexus SA is a France based biopharmaceutical company. It is engaged in developing drug candidates to be used in the treatment of central nervous system (CNS) disorders. The company's therapeutics platform is based on simultaneously targeting neurons and glial cells by creating and developing innovative combinations of two distinct drugs: a CNS drug targeting neuronal activity; and a drug targeting glial cells. The drug candidates of the organization are THN102 to treat excessive daytime sleepiness in Parkinson's disease, THN201 for the treatment of neurocognitive disorders in Alzheimer's disease and THN101 for neuropathic pain.

Theranexus Headlines

No Headlines